Corcept Therapeutics Inc (CORT) - News Archive

In the realm of pharmaceutical sciences, groundbreaking developments can have a profound impact on patient populations suffering from debilitating endocrine disorders. Corcept Therapeutics Incorporated, a prominent play...

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive loss of motor neurons, leading to muscle weakness, paralysis, and ultimately, death. Despite extensive rese...

Corcept Therapeutics Wraps Up the Enrollment in Crucial Phase 3 Rosella Trial of Relacorilant for Platinum-Resistant Ovarian Cancer Corcept Therapeutics Incorporated has announced the completion of enrollment in ROSELLA...

Corcept Therapeutics Incorporated, a California-based medical titan in the discovery and manufacturing of medical solutions addressing severe endocrinologic, metabolic, oncologic, and neurologic disorders, has successfu...

Corcept Announces Preliminary Results from Prevalence Phase of CATALYST Clinical TrialCorcept Therapeutics Incorporated (NASDAQ: CORT), a pioneering company focused on the development of medications to treat severe endo...

Combining Articles:Corcept Therapeutics Incorporated, a leading commercial-stage company specializing in the discovery and development of medications to address severe endocrinologic, oncologic, metabolic, and neurologi...

Corcept Therapeutics Reports Strong Financial Results and Promising Revenue Guidance for 2024 as the Company Announces Stock Repurchase ProgramIn a recent press release, Corcept Therapeutics Incorporated (NASDAQ: CORT)...